These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 34536944)

  • 1. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
    Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
    Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study.
    Fischer M; Moreno L; Ziegler DS; Marshall LV; Zwaan CM; Irwin MS; Casanova M; Sabado C; Wulff B; Stegert M; Wang L; Hurtado FK; Branle F; Geoerger B; Schulte JH
    Lancet Oncol; 2021 Dec; 22(12):1764-1776. PubMed ID: 34780709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.
    Mossé YP; Lim MS; Voss SD; Wilner K; Ruffner K; Laliberte J; Rolland D; Balis FM; Maris JM; Weigel BJ; Ingle AM; Ahern C; Adamson PC; Blaney SM
    Lancet Oncol; 2013 May; 14(6):472-80. PubMed ID: 23598171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson ADJ; Zwaan CM; Kolb EA; Karres D; Guillot J; Kim SY; Marshall L; Tasian SK; Smith M; Cooper T; Adamson PC; Barry E; Benettaib B; Binlich F; Borgman A; Brivio E; Capdeville R; Delgado D; Faller D; Fogelstrand L; Fraenkel PG; Hasle H; Heenen D; Kaspers G; Kieran M; Klusmann JH; Lesa G; Ligas F; Mappa S; Mohamed H; Moore A; Morris J; Nottage K; Reinhardt D; Scobie N; Simko S; Winkler T; Norga K; Reaman G; Vassal G
    Eur J Cancer; 2020 Sep; 136():116-129. PubMed ID: 32688206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Allen C; Fangusaro J; Hutter C; Witt O; Weiner S; Reaman G; Russo M; Bandopadhayay P; Ahsan S; Barone A; Barry E; de Rojas T; Fisher M; Fox E; Bender JG; Gore L; Hargrave D; Hawkins D; Kreider B; Langseth AJ; Lesa G; Ligas F; Marotti M; Marshall LV; Nasri K; Norga K; Nysom K; Pappo A; Rossato G; Scobie N; Smith M; Stieglitz E; Weigel B; Weinstein A; Viana R; Karres D; Vassal G
    Eur J Cancer; 2022 Dec; 177():120-142. PubMed ID: 36335782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
    Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib.
    Prokoph N; Matthews JD; Trigg RM; Montes-Mojarro IA; Burke GAA; Fend F; Merkel O; Kenner L; Geoerger B; Johnston R; Murray MJ; Riguad C; Brugières L; Turner SD
    Br J Haematol; 2023 Sep; 202(5):985-994. PubMed ID: 37357529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population modeling analyses of crizotinib in pediatric patients with ALK-positive advanced cancers.
    Jerry L; Swan L; Dana N; Balis FM; Greengard E; Huiping X
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31139. PubMed ID: 38867367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson ADJ; Federico S; Gatz SA; Ortiz M; Lesa G; Scobie N; Gounaris I; Weiner SL; Weigel B; Unger TJ; Stewart E; Smith M; Slotkin EK; Reaman G; Pappo A; Nysom K; Norga K; McDonough J; Marshall LV; Ludwinski D; Ligas F; Karres D; Kool M; Horner TJ; Henssen A; Heenen D; Hawkins DS; Gore L; Bender JG; Galluzzo S; Fox E; de Rojas T; Davies BR; Chakrabarti J; Carmichael J; Bradford D; Blanc P; Bernardi R; Benchetrit S; Akindele K; Vassal G
    Eur J Cancer; 2023 Sep; 190():112950. PubMed ID: 37441939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paediatric Strategy Forum for medicinal product development of multi-targeted kinase inhibitors in bone sarcomas: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Gaspar N; Janeway K; Campbell-Hewson Q; Lawlor ER; Copland C; Karres D; Norga K; Benzaghou F; Weiner S; Weigel B; Weiss AR; Strauss SJ; Smith M; Setty BA; Seibel N; Scobie N; Pappo A; Okpara CE; Nysom K; McDonough J; Marshall LV; Ludwinski D; Ligas F; Lesa G; Knudsen S; Kauh J; Hsieh A; Heenen D; Hawkins DS; Graham A; Garmey E; DuBois SG; Fox E; Donoghue M; de Rojas T; Chung J; Casanova M; Brennan B; Bishop M; Buenger V; Reaman G; Vassal G
    Eur J Cancer; 2022 Sep; 173():71-90. PubMed ID: 35863108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE.
    Schöffski P; Kubickova M; Wozniak A; Blay JY; Strauss SJ; Stacchiotti S; Switaj T; Bücklein V; Leahy MG; Italiano A; Isambert N; Debiec-Rychter M; Sciot R; Lee CJ; Speetjens FM; Nzokirantevye A; Neven A; Kasper B
    Eur J Cancer; 2021 Oct; 156():12-23. PubMed ID: 34392187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients.
    Pearson ADJ; Rossig C; Lesa G; Diede SJ; Weiner S; Anderson J; Gray J; Geoerger B; Minard-Colin V; Marshall LV; Smith M; Sondel P; Bajars M; Baldazzi C; Barry E; Blackman S; Blanc P; Capdeville R; Caron H; Cole PD; Jiménez JC; Demolis P; Donoghue M; Elgadi M; Gajewski T; Galluzzo S; Ilaria R; Jenkner A; Karres D; Kieran M; Ligas F; Lowy I; Meyers M; Oprea C; Peddareddigari VGR; Sterba J; Stockman PK; Suenaert P; Tabori U; van Tilburg C; Yancey T; Weigel B; Norga K; Reaman G; Vassal G
    Eur J Cancer; 2020 Mar; 127():52-66. PubMed ID: 31986450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study.
    Mossé YP; Voss SD; Lim MS; Rolland D; Minard CG; Fox E; Adamson P; Wilner K; Blaney SM; Weigel BJ
    J Clin Oncol; 2017 Oct; 35(28):3215-3221. PubMed ID: 28787259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase I/II Study of Crizotinib for Recurrent or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma and a Phase I Study of Crizotinib for Recurrent or Refractory Neuroblastoma : Study Protocol for a Multicenter Single-arm Open-label Trial.
    Sekimizu M; Osumi T; Fukano R; Koga Y; Kada A; Saito AM; Mori T
    Acta Med Okayama; 2018 Aug; 72(4):431-436. PubMed ID: 30140094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Podcast on Emerging Treatment Options for Pediatric Patients with ALK-Positive Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumors.
    Lowe E; Mossé YP
    Oncol Ther; 2024 Jun; 12(2):247-255. PubMed ID: 38676786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma.
    Moreno L; Barone G; DuBois SG; Molenaar J; Fischer M; Schulte J; Eggert A; Schleiermacher G; Speleman F; Chesler L; Geoerger B; Hogarty MD; Irwin MS; Bird N; Blanchard GB; Buckland S; Caron H; Davis S; De Wilde B; Deubzer HE; Dolman E; Eilers M; George RE; George S; Jaroslav Š; Maris JM; Marshall L; Merchant M; Mortimer P; Owens C; Philpott A; Poon E; Shay JW; Tonelli R; Valteau-Couanet D; Vassal G; Park JR; Pearson ADJ
    Eur J Cancer; 2020 Sep; 136():52-68. PubMed ID: 32653773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From bench to bedside: the past, present and future of therapy for systemic paediatric ALCL, ALK.
    Larose H; Burke GAA; Lowe EJ; Turner SD
    Br J Haematol; 2019 Jun; 185(6):1043-1054. PubMed ID: 30681723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma.
    Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K
    J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
    Fukano R; Mori T; Sekimizu M; Choi I; Kada A; Saito AM; Asada R; Takeuchi K; Terauchi T; Tateishi U; Horibe K; Nagai H
    Cancer Sci; 2020 Dec; 111(12):4540-4547. PubMed ID: 33010107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.